Session information

Luncheon Seminar

LS3-3 The Emerging Role of FLT3 inhibition in AML therapy

Sun. Oct 13, 2019 12:25 PM - 1:10 PM No.3 (Tokyo International Forum, 7F Hall B7(2))

Chair: Hitoshi Kiyoi（Nagoya University Graduate School of Medicine Department of Hematology and Oncology）

Sponsor: Astellas Pharma Inc.

[LS3-3] The Emerging Role of FLT3 inhibition in AML therapy

Alexander E. Perl (Associate Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania; Leukemia Program, Abramson Cancer Center at the University of Pennsylvania)

▲